InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.755 -0.28 (-27.05%)+
Announcement
Release
20 Apr 2026 9:04AM
Price at Release
$1.035
Full Release
download
Summary
Orthocell Limited reported robust financial performance in its Quarterly Activity Report for the period ending 31 March 2026. The company achieved a revenue of $3.2 million, primarily driven by the increased penetration of their product Remplir in existing markets, particularly in the U.S., where March saw significant sales growth. Orthocell expanded its distributor network to cover a large portion of the U.S. population and secured approvals across various hospital networks. The company maintains a strong cash position with reserves of $48 million, providing a liquidity runway of approximately 4.6 years. The report highlights ongoing commercialisation efforts, market expansions in Canada, the UK, and the EU, and strong engagement in defence settings.
Key Points
  • $3.2 million revenue achieved, with significant growth in the U.S. market.
  • Strong cash reserves of $48 million, offering a 4.6-year cash runway.
  • Expanded U.S. distributor network covers 16+ states and 40% of the population.
  • Remplir product used in 23 surgeries in Ukraine; approval secured for use in U.S. Department of Defence networks.
  • Market access program in the UK and EU is progressing on schedule with anticipated approvals.
  • Robust engagement in defence and commercial sectors globally with ongoing product training and sales commencement in Canada.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.